← All companies

Listed outside the U.S. See the CSE: RVV quote ↗

Why we cover it

A small Canadian company working across several areas at once: psilocybin, cannabis-related patents and a COVID drug.

Financials

Recent financials aren't available in a standard format for this company. See its listing ↗

In the Journal (3)

• Sep 29, 2026 Only 3 of 10 Psychedelic Companies Lobby Washington. One Just Joined — Twice, in the Same Quarter.
• Sep 23, 2026 Which Psychedelic-Company CEO's Pay Actually Matched Their Stock's Performance? We Checked All 10 — Almost None Did.
• Sep 11, 2026 The Psychedelic Money Rankings: $11 Billion Public, $1.6 Billion Private, $140 Million From Governments

Prices are end-of-day closes from Nasdaq; financials come from SEC filings. Not investment advice.